NCT07193862 2026-02-27
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
Northwell Health
Phase EARLY_PHASE1 Recruiting
Clinical Trials
16 trialsNCT04564898 2026-01-08
TriComB
Gruppo Oncologico del Nord-Ovest
Phase 1/2 Active not recruiting
NCT06332079 2026-01-05
HAITI
Gruppo Oncologico del Nord-Ovest
Phase 2 Terminated
NCT06540326 2025-12-22
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06764680 2025-08-24
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT07012954 2025-06-24
ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC
Sun Yat-sen University
Phase 1/2 Recruiting
NCT05727163 2025-05-30
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
Sun Yat-sen University
Phase 2 Recruiting
NCT06282445 2025-02-17
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 2 Recruiting
NCT04940546 2024-12-03
Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients
Sun Yat-sen University
Phase 1/2 Active not recruiting
NCT06682247 2024-11-12
A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer
Sun Yat-sen University
Not yet recruiting
NCT03164655 2024-10-01
SULTAN
UNICANCER
Phase 2 Completed
NCT06447727 2024-06-07
Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM
Zhongda Hospital
Recruiting
NCT01910610 2024-03-12
STRATEGIC-1
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 3 Active not recruiting
NCT04262687 2023-08-18
POCHI
Federation Francophone de Cancerologie Digestive
Phase 2 Unknown
NCT03923036 2019-04-22
AVOCETTE
University Hospital, Caen
Unknown
NCT01249638 2011-03-14
Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC
Ludwig-Maximilians - University of Munich
Phase 3 Unknown